Needham downgraded Penumbra (PEN) to Hold from Buy following the announcement of a deal to be acquired by Boston Scientific (BSX). The firm notes the “significant” premium that Boston Scientific is paying and also contends that competing bids are unlikely given potential antitrust issues for other large-cap med tech companies, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: